Answer
The terminal elimination half-life of intravenously administered ocrelizumab is 26 days.
Sources for this answer
- OCREVUS 300 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 22Document updated
Sources checked